Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription 09.06.2025 2 Am J Hematol 9 Ann Hematol 1 Biochem Biophys Res Commun 3 Blood 1 BMC Cancer 1 Bone Marrow Transplant 1 Clin Infect Dis 3 Eur J Haematol 1 Gene 1 Int J Hematol 1 J Biol Chem 3 J Clin Oncol 1 J Immunol 1 J Natl Cancer Inst 2 J Pediatr Hematol Oncol 2 Leuk Lymphoma 2 Leuk Res 3 Leukemia 2 N Engl J Med 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. STAGNO F, Cucci R, Marsili G, Castagnetti F, et al
   Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database.
   Am J Hematol. 2025 Jun 5. doi: 10.1002/ajh.27733.
   PubMed        
   
   
2. BAZARBACHI A, Galimard JE, Dalle IA, Socie G, et al
   Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP.
   Am J Hematol. 2025 May 30. doi: 10.1002/ajh.27726.
   PubMed         Abstract available
   
   

   
   Ann Hematol

3. CAO S, Cao C, Wang S
   Efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in aggressive NK-cell leukemia: a meta-analysis.
   Ann Hematol. 2025 Jun 5. doi: 10.1007/s00277-025-06423.
   PubMed         Abstract available
   
   
4. YOKOYAMA H, Fuji S, Murata M, Hirayama M, et al
   Impact of graft-versus-host disease on outcomes of cord blood transplantation according to HLA disparity and its prophylaxis type.
   Ann Hematol. 2025;104:2905-2913.
   PubMed         Abstract available
   
   
5. TURKINA A, Vinogradova O, Lomaia E, Shatokhina E, et al
   Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.
   Ann Hematol. 2025;104:2707-2715.
   PubMed         Abstract available
   
   
6. LIU J, Guo D, Lian H, Ding P, et al
   Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation.
   Ann Hematol. 2025;104:2915-2926.
   PubMed         Abstract available
   
   
7. MIAO L, Wang X, Yao M, Tao Y, et al
   Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis.
   Ann Hematol. 2025;104:2581-2591.
   PubMed         Abstract available
   
   
8. AN N, Bian K, Li C
   Alemtuzumab for haematological malignancies.
   Ann Hematol. 2025;104:2593-2603.
   PubMed         Abstract available
   
   
9. STUCKEY R, Navarrete Bullon L, Borrero Borrego A, Vidal Ballester V, et al
   Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs.
   Ann Hematol. 2025;104:3007-3009.
   PubMed         Abstract available
   
   
10. YANG X, Duan Y, Zhou C, Zhang N, et al
    A case series of B-Lymphoblastic lymphoma with C-MYC rearrangement in children: diagnostic and therapeutic challenges.
    Ann Hematol. 2025;104:3059-3066.
    PubMed         Abstract available
    
    
11. GARCIA M, Croizier C, Lazarian G, Quinquenel A, et al
    Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
    Ann Hematol. 2025;104:2889-2895.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

12. ZHANG X, Zhong L, Zhai L, Li H, et al
    IRF2-driven upregulation of OAS3 promotes AML cell proliferation by modulating the JAK-STAT signaling pathway.
    Biochem Biophys Res Commun. 2025;772:152064.
    PubMed         Abstract available
    
    

    
    Blood

13. KATER AP, Harrup R, Kipps TJ, Eichhorst B, et al
    The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
    Blood. 2025;145:2733-2745.
    PubMed         Abstract available
    
    
14. WIERDA WG, Eichhorst BF, Hallek MJ
    Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia.
    Blood. 2025 Jun 2:blood.2025028570. doi: 10.1182/blood.2025028570.
    PubMed         Abstract available
    
    
15. CHEN C, Xu J, Sussman JH, Vincent T, et al
    Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome.
    Blood. 2025;145:2685-2700.
    PubMed         Abstract available
    
    

    
    BMC Cancer

16. BAI JF, Wang T, Li JT, Zhang CL, et al
    Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study.
    BMC Cancer. 2025;25:990.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

17. CAVALLARO G, Lazzarotto D, Pavoni C, Valsecchi F, et al
    Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study.
    Bone Marrow Transplant. 2025 Jun 2. doi: 10.1038/s41409-025-02632.
    PubMed         Abstract available
    
    

    
    Clin Infect Dis

18. ROGERS JH, Westley B, Mego T, Newell KG, et al
    Fatal borealpox in an immunosuppressed patient treated with antivirals and vaccinia immunoglobulin - Alaska, 2023.
    Clin Infect Dis. 2024 Nov 5:ciae536. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

19. LI Y, Liu X, Li W, Hou L, et al
    Diagnostic and Prognostic Significance of Peripheral Blood RASSF1A, P16, and PTGER4 Gene Methylation in Adult Acute Leukemia.
    Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14442.
    PubMed         Abstract available
    
    
20. KRUSZEWSKI M, Schmoor C, Berg T, Rehman UU, et al
    Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.
    Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14426.
    PubMed         Abstract available
    
    
21. LOHRBERG M, Heber M, Ries L, Markus K, et al
    Dual Targeting of Pim and PI3 Kinases in Mature T-Cell Lymphoma.
    Eur J Haematol. 2025 Mar 31. doi: 10.1111/ejh.14420.
    PubMed         Abstract available
    
    

    
    Gene

22. GUAN B, Liu L, Liu Y
    Application and characterisation of four genetically engineered animal models (mouse/zebrafish/rhesus monkey/Drosophila) in acute myeloid leukemia.
    Gene. 2025 Jun 3:149607. doi: 10.1016/j.gene.2025.149607.
    PubMed         Abstract available
    
    

    
    Int J Hematol

23. NOSAKA K, Fukushima T
    JSH practical guidelines for hematological malignancies, 2023: II. lymphoma 9-adult T-cell leukemia-lymphoma (ATL).
    Int J Hematol. 2025 Jun 4. doi: 10.1007/s12185-025-04011.
    PubMed        
    
    

    
    J Biol Chem

24. SANG X, Guan Y, Jiang M, Chen X, et al
    Molecular Insights into Chemotherapy Resistance Mediated by MLL-AF9 Fusion Gene in Pediatric B-Cell Acute Lymphoblastic Leukemia.
    J Biol Chem. 2025 May 30:110321. doi: 10.1016/j.jbc.2025.110321.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

25. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
    Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
    J Clin Oncol. 2025 Jun 6:JCO2500166. doi: 10.1200/JCO-25-00166.
    PubMed         Abstract available
    
    
26. SHADMAN M, Munir T, Ma S, Lasica M, et al
    Zanubrutinib and Venetoclax for Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
    J Clin Oncol. 2025 May 31:JCO2500758. doi: 10.1200/JCO-25-00758.
    PubMed         Abstract available
    
    
27. HUANG BJ, Meyer LK, Alonzo TA, Wang YC, et al
    Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.
    J Clin Oncol. 2025;43:1961-1971.
    PubMed         Abstract available
    
    

    
    J Immunol

28. WANG G, Luo TY, Shi Y, Surya A, et al
    Effect of statins on IL-10 signaling and production by chronic lymphocytic leukemia cells.
    J Immunol. 2025 Jun 2:vkaf103. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

29. 
    Correction to: Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2025 May 30:djaf124. doi: 10.1093.
    PubMed        
    
    

    
    J Pediatr Hematol Oncol

30. HILL R, Thomas L, Farbo D, Heym K, et al
    Exocrine Pancreatic Insufficiency Following Asparaginase-induced Pancreatitis in Pediatric Acute Lymphoblastic Leukemia Patients: A Case Series.
    J Pediatr Hematol Oncol. 2025 Jun 6. doi: 10.1097/MPH.0000000000003058.
    PubMed         Abstract available
    
    
31. WEN X, Gao C, Li W, Zhang Y, et al
    Effects of Genetic Polymorphisms of WNT Signaling Pathway on the Prognosis of Acute Lymphoblastic Leukemia in Chinese Pediatric Population.
    J Pediatr Hematol Oncol. 2025 Jun 2. doi: 10.1097/MPH.0000000000003037.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

32. JANY J, Mikesch JH, Wethmar K, Baden D, et al
    Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).
    Leuk Lymphoma. 2025 Jun 2:1-12. doi: 10.1080/10428194.2025.2512029.
    PubMed         Abstract available
    
    
33. KAMALLOO H, Fathi M, Bavandi S, Asadi F, et al
    Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jun 2:1-13. doi: 10.1080/10428194.2025.2507198.
    PubMed         Abstract available
    
    

    
    Leuk Res

34. HASLINGER S, Schinnerl D, Konig M, Inthal A, et al
    Identification of a novel amplified PAX5::RBPMS fusion gene in pediatric B-cell acute lymphoblastic leukemia.
    Leuk Res. 2025;154:107722.
    PubMed        
    
    
35. HAMMAMI MB, Qasim A, Shah A, Zhang H, et al
    Cutaneous manifestations of large granular lymphocytic leukemia: A case report and systematic review.
    Leuk Res. 2025;154:107720.
    PubMed        
    
    

    
    Leukemia

36. IKOMA Y, Nakamura N, Kaneda Y, Takamori H, et al
    Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
    Leukemia. 2025;39:1362-1367.
    PubMed         Abstract available
    
    
37. BUCKLEY M, Yeung DT, White DL, Eadie LN, et al
    T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.
    Leukemia. 2025;39:1294-1310.
    PubMed         Abstract available
    
    
38. VELETIC I, Harris DM, Rozovski U, Bertilaccio MTS, et al
    CLL cell-derived exosomes alter the immune and hematopoietic systems.
    Leukemia. 2025;39:1380-1394.
    PubMed         Abstract available
    
    

    
    N Engl J Med

39. BROWN JR, Miller K, Munugalavadla V
    Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. Reply.
    N Engl J Med. 2025;392:2181.
    PubMed        
    
    
40. MOHTY M, Kharfan-Dabaja MA
    Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
    N Engl J Med. 2025;392:2180-2181.
    PubMed        
    
    

    
    PLoS One

41. OURU PA, Zheng H, Lin Z, Yang M, et al
    A multicenter cross-sectional study on factors associated with caregiving appraisal in pediatric acute leukemia caregivers.
    PLoS One. 2025;20:e0324589.
    PubMed         Abstract available
    
    
42. KASSA E, Ayalew M, Birhan M, Gelaw A, et al
    Clinical profile and treatment outcomes of acute lymphoblastic leukemia among children attending at the University of Gondar comprehensive specialized hospital and Tikur Anbessa Specialized Hospital in Ethiopia.
    PLoS One. 2025;20:e0322747.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.